Working… Menu

NeoVax + CDX-301 and Nivolumab in Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04930783
Recruitment Status : Not yet recruiting
First Posted : June 18, 2021
Last Update Posted : June 18, 2021
Celldex Therapeutics
Information provided by (Responsible Party):
Patrick Ott, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : January 31, 2027